Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

Stopped 1.) Not possible to recruit the planned number of patients during the planned study period; 2.) "Dexamethason" was included in the standard of care for the study population during the course of the study and inclusion criteria could no longer be met.

Conditions

• SARS-CoV-2 Infection

Interventions

• DRUG: Tocilizumab (TCZ)
• DRUG: Placebo

Sponsor

Insel Gruppe AG, University Hospital Bern

Collaborators

• [object Object]